Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cytokine ; 12(1): 1-7, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10623435

ABSTRACT

In bone marrow, haematopoietic stem cells (HSC) rely on close contact with stromal cells for proliferation and differentiation. Stromal cell-derived factor (SDF-1) is a chemokine produced by bone marrow stromal cells and has been reported to be a chemoattractant for CD34(+)cells. SDF-1 was evaluated for effects on proliferation of both mature and immature human progenitor cells in vitro. Neither proliferation nor maturation of peripheral blood cells was stimulated by SDF-1 alone. Moreover, we have previously demonstrated that 5-fluorouracile (5-FU) resistant HSC require a combination of interleukin 12 (IL-12), IL-6 and SCF for the production of morphologically recognizable clonogenic elements at day 14 in semisolid medium. Our data reported a strong enhancement of the IL-6, IL-12, SCF-induced synergism (172%) by SDF-1 (296.5%). Furthermore, our data suggest that this chemokine alone had no effect on triggering quiescent cells and may preserve these cells from 5-FU cell damage or upregulate early-acting cytokine receptors. Thus, SDF-1 might play a key role in early human haematopoiesis through its potent synergistic effects in combination with early-acting cytokines. These results suggest that a programmed response to sequential cytokine stimulation may be part of a control mechanism required for maintenance of proliferation of primitive HSC.


Subject(s)
Blood Cells/cytology , Chemokines, CXC/physiology , Hematopoiesis/physiology , Hematopoietic Stem Cells/cytology , Interleukin-12/physiology , Interleukin-6/physiology , Stromal Cells/cytology , Antimetabolites/adverse effects , Blood Cells/drug effects , Cell Division/drug effects , Cells, Cultured , Chemokine CXCL12 , Cytokines/physiology , Erythroid Precursor Cells/cytology , Fluorouracil/adverse effects , Hematopoiesis/drug effects , Hematopoietic Stem Cells/drug effects , Humans , Stromal Cells/drug effects
2.
Am J Hematol ; 62(2): 65-73, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10508999

ABSTRACT

It has been shown that hematopoietic progenitors can be expanded ex vivo in the presence of various cytokine combinations. Glucocorticoids (GC) are involved in the self-renewal of erythroid progenitors in chicken. To see whether GC have a similar effect on hematopoiesis in humans, CD34(+) peripheral blood stem cells were cultured in serum free medium in the presence of a GC, triamcinolone acetonide. However, our results demonstrate an inhibition of both erythroid and granulocyte-macrophage (GM) proliferation and a modification of erythroid colony morphology. Furthermore, RU38486 (Mifepristone), a potent GC antagonist, was unable to reverse the inhibitory effect of triamcinolone acetonide. We also identified and characterized another steroid subfamily, the mineralocorticoid (MC) subfamily, in human PB CD34(+) cells. The MC, aldosterone, significantly enhanced GM colony formation and diminished the erythroid colony number. Neither of effects were inhibited by ZK91587, an antagonist specific to the MC receptor (MCR). In contrast, ZK91587 reversed the stimulatory effect of deoxycorticosterone on GM colony formation. Cytoplasmic staining for MCR was observed in CD34(+) cells incubated with a polyclonal antiserum raised against human MCR. To our knowledge, this is the first demonstration of the presence of MCR in human PB CD34(+) cells.


Subject(s)
Aldosterone/pharmacology , Desoxycorticosterone/pharmacology , Glucocorticoids/pharmacology , Hematopoietic Stem Cell Mobilization , Hematopoietic Stem Cells/cytology , Mineralocorticoids/pharmacology , Triamcinolone Acetonide/pharmacology , Adult , Cells, Cultured , Colony-Forming Units Assay , Erythropoietin/pharmacology , Granulocyte Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cells/drug effects , Humans , Interleukin-3/pharmacology , Mifepristone/pharmacology , Mineralocorticoids/antagonists & inhibitors , Recombinant Proteins/pharmacology , Spironolactone/analogs & derivatives , Spironolactone/pharmacology
3.
Br J Haematol ; 105(1): 33-9, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10233360

ABSTRACT

Interleukin-12 (IL-12), a heterodimeric cytokine with potent biological activity, was evaluated for effects on proliferation of human immature progenitor cells in vitro. In vitro proliferation of 5-FU-resistant CD34+ (G0) peripheral blood stem cells (PBSC) in response to sequential cytokine stimulation was examined in the presence and absence of 100 ng/ml IL-12. PBSC were found to include a subpopulation of cells that were resistant to 25 microg/ml 5-FU and required a combination of IL-12, IL-6 and SCF for the production of morphologically recognizable clonogenic elements at day 14 in semisolid medium. Furthermore, addition of IL-6 soluble receptor (IL-6Rs) to IL-6 and SCF led to a similar recruitment. We also demonstrated a significant production of IL-6Rs by CD34+ cells stimulated by IL-12. We noted that glucocorticoids and aldosterone, a mineralocorticoid, had a positive effect on recruitment, but neither mineralocorticoid nor glucocorticoids induced IL-6Rs production by CD34+ cells. The recruitment mechanism by steroids seemed to be different from that used by IL-12. These results confirm previous findings which showed the involvement of IL-12 on immature PBSCs and suggest that IL-12 might play a key role in early haemopoiesis.


Subject(s)
Hematopoietic Stem Cells/cytology , Interleukin-12/pharmacology , Interleukin-6/pharmacology , Antigens, CD34 , Cell Differentiation/physiology , Culture Media, Serum-Free , Drug Synergism , Fluorouracil/pharmacology , Humans , Receptors, Interleukin-6/metabolism , Stem Cell Factor
SELECTION OF CITATIONS
SEARCH DETAIL
...